PubRank

Cancer genomics & proteomics (Cancer Genomics Proteomics)

Journal PubWeight™ 245.77‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. 2006 1.94
2 Cancer-related issues of CD147. 2010 1.74
3 MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. 2009 1.55
4 Global Proteomic Profiling of Drosophila Ovary: A High-resolution, Unbiased, Accurate and Multifaceted Analysis. 2015 1.44
5 Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. 2009 1.41
6 Individualization of therapy using Mammaprint: from development to the MINDACT Trial. 2007 1.38
7 SOX2 expression and amplification in gliomas and glioma cell lines. 2011 1.35
8 Proteomic based identification of manganese superoxide dismutase 2 (SOD2) as a metastasis marker for oral squamous cell carcinoma. 2008 1.34
9 Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. 2009 1.26
10 Discovery of oral fluid biomarkers for human oral cancer by mass spectrometry. 2007 1.25
11 IL-6 enhances the nuclear translocation of DNA cytosine-5-methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence by the AKT kinase. 2008 1.23
12 Breast cancer metastasis. 2012 1.18
13 Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. 2013 1.17
14 Are we missing the target? Cancer stem cells and drug resistance in non-small cell lung cancer. 2012 1.05
15 The proteome profile of the human osteosarcoma U2OS cell line. 2008 1.05
16 Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. 2013 1.05
17 Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. 2007 1.04
18 MicroRNA expression profile of MCF-7 human breast cancer cells and the effect of green tea polyphenon-60. 2010 1.04
19 Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. 2014 1.04
20 ALCAM/CD166: cancer-related issues. 2010 1.03
21 Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. 2007 1.03
22 Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. 2009 1.01
23 Metastasis from oral cancer: an overview. 2012 1.00
24 Effect of dietary genistein on Phase II and antioxidant enzymes in rat liver. 2009 1.00
25 Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. 2010 1.00
26 CDH11 expression is associated with survival in patients with osteosarcoma. 2008 1.00
27 Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. 2005 0.99
28 Identification of melanoma antigens using a Serological Proteome Approach (SERPA). 2010 0.99
29 Genome-wide expression profiling reveals new insights into pathogenesis and progression of testicular germ cell tumors. 2007 0.99
30 The cancer biomarker osteopontin: combination with other markers. 2011 0.98
31 Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. 2007 0.98
32 Interaction of methylenetetrahydrofolate reductase genotype and smoking habit in Taiwanese lung cancer patients. 2010 0.97
33 Dissection of the Process of Brain Metastasis Reveals Targets and Mechanisms for Molecular-based Intervention. 2016 0.97
34 Comparative clinical and transcriptomal profiles of breast cancer between French and South Mediterranean patients show minor but significative biological differences. 2009 0.96
35 Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. 2010 0.96
36 Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2'-deoxycytidine, microarray and gene expression profile. 2012 0.96
37 A genetic variant located in miR-423 is associated with reduced breast cancer risk. 2012 0.95
38 Pathogenetic and clinical relevance of microRNAs in colorectal cancer. 2009 0.95
39 Prognostic utility of glycosyltransferase expression in breast cancer. 2009 0.94
40 The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas. 2009 0.94
41 Parthenolide, an NF-κB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. 2011 0.94
42 Increased levels of macrophage-secreted cathepsin S during prostate cancer progression in TRAMP mice and patients. 2009 0.93
43 Concurrent down-regulation of Egr-1 and gelsolin in the majority of human breast cancer cells. 2008 0.93
44 Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy. 2007 0.93
45 A Novel Approach to Evaluating Cancer Driver Gene Mutation Densities: Cytoskeleton-related Gene Candidates. 2015 0.93
46 Synthetic lethality-based targets for discovery of new cancer therapeutics. 2011 0.92
47 Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. 2012 0.92
48 Cancer stem cells and individualized therapy. 2007 0.91
49 Proteomic analysis of archival breast cancer serum. 2009 0.91
50 Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer. 2013 0.90
Next 50